MERCI 1 - A phase 1 study of mechanical embolus removal in cerebral ischemia

被引:317
作者
Gobin, YP
Starkman, S
Duckwiler, GR
Grobelny, T
Kidwell, CS
Jahan, R
Pile-Spellman, J
Segal, A
Vinuela, F
Saver, JL
机构
[1] Weill Cornell Med Coll, New York Presbyterian Hosp, Div Intervent Neuroradiol, New York, NY 10021 USA
[2] Univ Calif Los Angeles, Stroke Study Network, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Ctr Emergency Med, Los Angeles, CA 90024 USA
[4] Univ Calif Los Angeles, Dept Radiol Sci, Div Intervent Neuroradiol, Los Angeles, CA 90024 USA
[5] St Lukes Hosp, Dept Radiol, Kansas City, MO USA
[6] Univ Calif Los Angeles, Stroke Unit, Los Angeles, CA USA
[7] Univ Calif Los Angeles, Sch Med, Dept Neurol,Reed Neurol Res Ctr, Comprehens Stroke & Vasc Neurol Program, Los Angeles, CA 90024 USA
[8] Columbia Univ, Milstein Hosp, Dept Radiol Neurosurg & Neurol, New York, NY USA
[9] Weill Cornell Med Coll, New York Presbyterian Hosp, Dept Neurol, New York, NY USA
[10] Univ Calif Los Angeles, Med Ctr, Dept Radiol Sci, Los Angeles, CA 90024 USA
关键词
embolectomy; stroke; ischemic; thrombectomy; thrombolytic therapy;
D O I
10.1161/01.STR.0000147718.12954.60
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-To report the result of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) 1 study, a phase 1 trial to evaluate the safety and efficacy of mechanical embolectomy in the cerebral vasculature. Methods-MERCI 1 enrolled 30 patients in 7 US centers. Main inclusion criteria were: National Institutes of Health Stroke Scale score (NIHSS) greater than or equal to10; treatment performed within 8 hours from symptoms onset and contra-indication to intravenous thrombolysis; no large hypodensity on computed tomography; and occlusion of a major cerebral artery on the angiogram. Safety was defined by the absence of vascular injury or symptomatic intracranial hemorrhage. Efficacy was assessed by recanalization rate and clinical outcome at 1 month. Significant recovery was defined as 30-day modified Rankin of 0 to 2 in patients with baseline NIHSS 10 to 20 and 30-day modified Rankin of 0 to 3 in patients with baseline NIHSS >20. The procedures were performed with the Merci Retrieval System, a system specially designed for intracranial embolectomy. Results-Twenty-eight patients were treated. Median NIHSS was 22. Median time from onset to completion of treatment was 6 hours and 15 minutes. Successful recanalization with mechanical embolectomy only was achieved in 12 (43%) patients, and with additional intra-arterial tissue plasminogen activator in 18 (64%) patients. There was one procedure related technical complication, with no clinical consequence. Twelve asymptomatic and no symptomatic intracranial hemorrhages occurred. At 1 month, 9 of 8 revascularized patients and 0 of 10 nonrevascularized patients had achieved significant recovery. Conclusion-This phase 1 study shows that cerebral embolectomy with the Merci Retriever was safe and that successful recanalization could benefit a significant number of patients, even when performed in an extended 8-hour time window.
引用
收藏
页码:2848 / 2853
页数:6
相关论文
共 20 条
[1]   Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].
Clark, WM ;
Wissman, S ;
Albers, GW ;
Jhamandas, JH ;
Madden, KP ;
Hamilton, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026
[2]   The rtPA (Alteplase) 0-to 6-hour acute stroke trial, part A (A0276g) - Results of a double-blind, placebo-controlled, multicenter study [J].
Clark, WM ;
Albers, GW ;
Madden, KP ;
Hamilton, S .
STROKE, 2000, 31 (04) :811-816
[3]  
DAVIE JC, 1967, J NEUROSURG, V27, P171
[4]   Effect of ultrasound on thrombolysis of middle cerebral artery occlusion [J].
Eggers, J ;
Koch, B ;
Meyer, K ;
König, I ;
Seidel, G .
ANNALS OF NEUROLOGY, 2003, 53 (06) :797-800
[5]  
FOGARTY TJ, 1963, SURG GYNECOL OBSTET, V116, P241
[6]   Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial [J].
Furlan, A ;
Higashida, R ;
Wechsler, L ;
Gent, M ;
Rowley, H ;
Kase, C ;
Pessin, M ;
Ahuja, A ;
Callahan, F ;
Clark, WM ;
Silver, F ;
Rivera, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2003-2011
[7]   CVA: Reducing the risk of a confused vascular analysis - The Feinberg lecture [J].
Furlan, AJ .
STROKE, 2000, 31 (06) :1451-1456
[8]   Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].
Hacke, W ;
Kaste, M ;
Fieschi, C ;
von Kummer, R ;
Davalos, A ;
Meier, D ;
Larrue, V ;
Bluhmki, E ;
Davis, S ;
Donnan, G ;
Schneider, D ;
Diez-Tejedor, E ;
Trouillas, P .
LANCET, 1998, 352 (9136) :1245-1251
[9]  
HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
[10]   Use of tissue-type plasminogen activator for acute ischemic stroke - The Cleveland area experience [J].
Katzan, IL ;
Furlan, AJ ;
Lloyd, LE ;
Frank, JI ;
Harper, DL ;
Hinchey, JA ;
Hammel, JP ;
Qu, A ;
Sila, CA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1151-1158